Exhibit 99.1
CANTEL MEDICAL CORP.
150 Clove Road
Little Falls, New Jersey 07424
FOR IMMEDIATE RELEASE
Contact: | Andrew A. Krakauer | | Richard E. Moyer |
| President | | Cameron Associates, Inc. |
| Cantel Medical Corp. | | richard@cameronassoc.com |
| Phone: (973) 890-7220 | | Phone: (212) 554-5466 |
CANTEL MEDICAL REPORTS 75% INCREASE IN NET INCOME - EPS OF $0.23 vs. $0.13 FOR QUARTER ENDED JANUARY 31, 2009
LITTLE FALLS, New Jersey (March 9, 2009) ... CANTEL MEDICAL CORP. (NYSE:CMN) reported a 75% increase in net income to $3,774,000, or $0.23 per diluted share, on a 2.5% increase in sales to $62,420,000 for the second quarter ended January 31, 2009. This compares with net income of $2,157,000, or $0.13 per diluted share, on sales of $60,910,000 for the second quarter ended January 31, 2008. For the six months ended January 31, 2009, the Company reported a 74% increase in net income to $7,107,000, or $0.43 per diluted share (inclusive of $0.02 of expenses related to the relocation of its Dutch manufacturing operations to the United States), on a 5% increase in sales to $126,826,000. This compares with net income of $4,096,000, or $0.25 per diluted share, on sales of $120,915,000 for the six months ended January 31, 2008.
Andrew Krakauer, Cantel’s President stated, “We are very pleased to have delivered another quarter of substantial earnings growth and our strongest quarterly performance of the past few years. These positive results confirm the continued success of our sales and marketing investments and various initiatives to improve operating margins. Cantel demonstrated sales growth in all reporting segments except for Water Purification and Filtration which was affected by some delayed capital sales and an unusually favorable comparative quarter in the prior year.”
Krakauer added, “While all our businesses performed well, operating income in our Endoscope Reprocessing and Dialysis units was substantially ahead of last year, aided by strong sales of consumables, including disinfectants, sterilants and an increase in service revenue. Additionally, the positive performance was helped by our active cost reduction and margin improvement programs, the implementation of price increases and reduced interest expenses.”
Krakauer continued, “Although our businesses are not immune to the economic downturn, we remain focused on our strategies to grow and improve performance. In this economy, our competitive advantage is our leadership positions in several infection prevention and control markets, a quality reputation and strong brands. Further, we have proactively developed our business to where approximately 70% of our sales come from disposables and service, which are supported by a large installed base of equipment.”
The Company further reported that its balance sheet at January 31, 2009 included current assets of $85,728,000, including cash of $20,052,000, a current ratio of 2.4:1, debt of $54,300,000, stockholders’ equity of $171,838,000 and a ratio of funded debt to equity of .32:1. Krakauer stated, “The Company has a strong balance sheet and continues to generate significant cash. Our cash provided by operating activities for the quarter was $7,801,000. We have reduced our net debt position from the first quarter by 18% to $34.2 million, which is less than one (1x) turn of our trailing EBITDAS.”
Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.
The Company will hold a conference call to discuss the results for the second quarter ended January 31, 2009 on Monday, March 9, 2009 at 11:00 AM Eastern time. To participate in the conference call, dial 1-877-407-8035 approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Monday, March 9 at 2:00 PM through midnight on March 10, by dialing 1-877-660-6853 and using passcode #286 and conference ID #315449.
The call will be simultaneously broadcast live over the Internet on vcall.com at http://www.investorcalendar.com/IC/CEPage.asp?ID=142021. A replay of the webcast will be available on Vcall for 30 days.
For further information, visit the Cantel website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel’s filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
2
CANTEL MEDICAL CORP.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
| | Three Months Ended | | Six Months Ended | |
| | January 31, | | January 31, | |
| | 2009 | | 2008 | | 2009 | | 2008 | |
| | | | | | | | | |
Net sales | | $ | 62,420 | | $ | 60,910 | | $ | 126,826 | | $ | 120,915 | |
| | | | | | | | | |
Cost of sales | | 38,809 | | 39,424 | | 79,592 | | 78,223 | |
| | | | | | | | | |
Gross profit | | 23,611 | | 21,486 | | 47,234 | | 42,692 | |
| | | | | | | | | |
Expenses: | | | | | | | | | |
Selling | | 6,992 | | 6,836 | | 14,342 | | 13,625 | |
General and administrative | | 9,037 | | 8,967 | | 18,061 | | 17,924 | |
Research and development | | 983 | | 961 | | 2,048 | | 1,951 | |
Total operating expenses | | 17,012 | | 16,764 | | 34,451 | | 33,500 | |
| | | | | | | | | |
Income before interest and income taxes | | 6,599 | | 4,722 | | 12,783 | | 9,192 | |
| | | | | | | | | |
Interest expense | | 674 | | 1,255 | | 1,425 | | 2,477 | |
Interest income | | (38 | ) | (150 | ) | (108 | ) | (297 | ) |
| | | | | | | | | |
Income before income taxes | | 5,963 | | 3,617 | | 11,466 | | 7,012 | |
| | | | | | | | | |
Income taxes | | 2,189 | | 1,460 | | 4,359 | | 2,916 | |
| | | | | | | | | |
Net income | | $ | 3,774 | | $ | 2,157 | | $ | 7,107 | | $ | 4,096 | |
| | | | | | | | | |
Earnings per common share - diluted | | $ | 0.23 | | $ | 0.13 | | $ | 0.43 | | $ | 0.25 | |
| | | | | | | | | |
Weighted average shares - diluted | | 16,415 | | 16,386 | | 16,382 | | 16,359 | |
CANTEL MEDICAL CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
| | January 31, | | July 31, | |
| | 2009 | | 2008 | |
Assets | | | | | |
Current assets | | $ | 85,728 | | $ | 84,561 | |
Property and equipment, net | | 36,248 | | 37,920 | |
Intangible assets | | 37,972 | | 41,254 | |
Goodwill | | 111,860 | | 113,958 | |
Other assets | | 1,084 | | 1,497 | |
| | $ | 272,892 | | $ | 279,190 | |
| | | | | |
Liabilities and stockholders’ equity | | | | | |
Current portion of long-term debt | | $ | 9,000 | | $ | 8,000 | |
Other current liabilities | | 27,438 | | 30,922 | |
Long-term debt | | 45,300 | | 50,300 | |
Other long-term liabilities | | 19,316 | | 21,256 | |
Stockholders’ equity | | 171,838 | | 168,712 | |
| | $ | 272,892 | | $ | 279,190 | |
SUPPLEMENTARY INFORMATION
Reconciliation of Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-Based Compensation Expense (“EBITDAS”)
The reconciliation of EBITDAS with net income for the three and six months ended January 31, 2009 and 2008, respectively, is as follows (in thousands):
| | Three Months Ended | | Six Months Ended | |
| | January 31, | | January 31, | |
| | 2009 | | 2008 | | 2009 | | 2008 | |
| | | | | | | | | |
Net income | | $ | 3,774 | | $ | 2,157 | | $ | 7,107 | | $ | 4,096 | |
| | | | | | | | | |
Income taxes | | 2,189 | | 1,460 | | 4,359 | | 2,916 | |
Interest expense | | 674 | | 1,255 | | 1,425 | | 2,477 | |
Interest income | | (38 | ) | (150 | ) | (108 | ) | (297 | ) |
Depreciation | | 1,525 | | 1,530 | | 3,075 | | 2,975 | |
Amortization | | 1,268 | | 1,460 | | 2,606 | | 2,859 | |
Loss on disposal of fixed assets | | 8 | | 49 | | 22 | | 49 | |
| | | | | | | | | |
EBITDA | | 9,400 | | 7,761 | | 18,486 | | 15,075 | |
| | | | | | | | | |
Stock-based compensation expense | | 525 | | 462 | | 1,045 | | 994 | |
| | | | | | | | | |
EBITDAS | | $ | 9,925 | | $ | 8,223 | | $ | 19,531 | | $ | 16,069 | |
EBITDAS is a measure of the Company’s performance that is not required by, or presented in accordance with, Generally Accepted Accounting Principles (“GAAP”). EBITDAS is a non-GAAP financial measure defined by the Company as income before interest, taxes, depreciation, amortization and stock-based compensation expense. The Company believes EBITDAS is an important valuation measurement for management and investors given the increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitions and depreciation of capital equipment, has on the Company’s net income. In particular, acquisitions have historically resulted in significant increases in amortization of intangible assets that reduced the Company’s net income. Additionally, the Company regards EBITDAS as a useful measure of operating performance and cash flow before the effect of interest expense and complements operating income, net income and other GAAP financial performance measures. Generally, a non-GAAP financial measure is a numerical measure of a Company’s performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. This measure, however, should be considered in addition to, and not as a substitute or superior to, net income, cash flows, or other measures of financial performance prepared in accordance with GAAP.
